U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205159) titled 'A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.' on Sept. 25.
Brief Summary: This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Alopecia Areata
Intervention:
DRUG: FB102
Route of administration- Intravenous (IV)
DRUG: Placebo
Route of administration- Intravenous (IV)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Forte Biosciences, Inc.
Published by HT Digital Content Services with per...